A small side benefit of having 30% in immunotherapies, while it is being funded with $18m, is that as our third pillar, it keeps AHZ a little more complex.
Clearly AHZ has the potential to be $10 in 5 years. However, biotech / medtech is an industry sector rife with takeovers. The more complex (and higher market cap / PE ratio) the less palatable we are for an opportunistic $1 or $2 takeover.
Letter of intent to fund Vacs, page-94
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$11.90 |
Change
1.050(9.68%) |
Mkt cap ! $251.5M | |||
| Open | High | Low | Value | Volume |
| $11.00 | $11.90 | $10.85 | $504.4K | 45.27K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $11.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $11.90 | 99 | 1 |
View Market Depth
| Last trade - 16.10pm 10/09/2024 (20 minute delay) ? |
| AVR (ASX) Chart |